AtriCure, Inc. provides innovative technologies for the treatment of AF and related conditions. AF affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of AF and reduction of AF related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent AF the most widely used LAA management devices in the world. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.